2025-09-23 - Analysis Report
Okay, here's an analysis of TEM (Unknown Company) based on the data provided. I'll present the information in English with a focus on key figures and concise interpretations.

**1. Performance vs. S&P 500 (VOO)**

*   **Company Overview:** TEM is an Unknown Company.

*   **Cumulative Return:**
    *   TEM: 59.79%
    *   VOO (S&P 500): 26.54%

*   **Outperformance (Spread):**
    *   Current: 32.1
    *   Range (Max: 102.9, Min: -25.4)
    *   Relative Spread: 44.8 (This indicates that TEM's current outperformance is positioned at the 44.8th percentile of its historical outperformance range.)

*   **Alpha, Beta Analysis (2023-2025):**

    | Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
    |------------|------|------|-------|------|-------|
    | 2023-2025  | 60.0% | 75.0% | 34.0% | -0.0 | 15.3 |

    *   **Analysis:** TEM significantly outperformed the market (positive Alpha). The Beta is almost zero, suggesting very little correlation with the S&P 500's movements. However, the Maximum Drawdown (MDD) is very high (75%), indicating significant volatility and risk.  The CAGR of 60% is substantial.

**2. Recent Price Action**

*   **Current Price:** 88.24 (Last Market Price: 85.87, change -2.69)
*   **Moving Averages:**
    *   5-day MA: 86.79
    *   20-day MA: 80.79
    *   60-day MA: 68.60

*   **Analysis:** The price is above all moving averages, which is generally a bullish signal.  However, the price has fallen, so it's important to watch for a trend reversal. The recent market price change is significant (-2.69), indicating short-term volatility.

**3. Market Risk Indicators & Expected Return**

*   **Market Risk Indicator (MRI):** 0.3367 (Low Risk)
*   **RSI:** 70.79 (Approaching overbought territory)
*   **PPO:** 0.1574 (Positive, suggesting an upward trend)
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (2 shares - Caution - MRI:0.33)
*   **Delta_Previous_Relative_Divergence:** -3.6 (Negative, indicating a short-term decrease in relative performance compared to the benchmark)
*   **Expected Return:** NaN (Likely missing data - a key piece of information)

*   **Analysis:** The MRI suggests low market risk. However, the RSI is nearing overbought levels, suggesting a potential pullback. The negative change in relative divergence supports this potential short-term weakness. The hybrid signal recommend to buy 80% of cash, showing that market consider now as good to invest. Since Expected Return is missing it is hard to estimate the future performance of the stock.

**4. Recent News & Significant Events (Yahoo Finance)**

*   **Key Headlines (All within the last week):**
    *   Multiple FDA clearances for Tempus AI's diagnostic devices (xR IVD, cardiac imaging platform, radiology portfolio via Pixel acquisition)
    *   Analyst and media commentary on Tempus AI's surge since IPO, boosted by FDA clearances
    *   General industry report on the growth of the cell therapy market.

*   **Analysis:** The news is overwhelmingly positive, focusing on regulatory approvals and their impact on Tempus AI's growth prospects. This likely explains the recent price surge.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (Mean: 2.15)
*   **Target Price:**
    *   Average: 73.45
    *   High: 98.00
    *   Low: 60.00
*   **Recent Rating Changes:** None available.

*   **Analysis:** Analyst sentiment is generally positive (Buy rating). The average target price is below the current price, suggesting limited upside potential or even a possible correction.  The wide range in target prices (60.00 to 98.00) indicates some uncertainty among analysts.

**5. Recent Earnings Analysis**

| 날짜       | EPS   | 예상 EPS  |
|------------|-------|-----------|
| 2025-08-08 | -0.22 | -0.22988  |
| 2025-05-06 | -0.24 | -0.26003  |
| 2025-02-24 | -0.18 | -0.15     |
| 2024-11-04 | -0.25 | -0.26608  |
| 2024-08-06 | -0.63 | -0.59     |

*   **Analysis:**  TEM is not yet profitable. The company has consistently beat EPS estimates in recent quarters, which is a positive sign. However, the losses are still significant.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-06-30 | $0.31B  | 61.99%        |
| 2025-03-31 | $0.26B  | 60.69%        |
| 2024-12-31 | $0.20B  | 60.83%        |
| 2024-09-30 | $0.18B  | 58.50%        |
| 2024-06-30 | $0.17B  | 45.50%        |

**Capital and Profitability:**

| Quarter    | Equity  | ROE       |
|------------|---------|-----------|
| 2025-06-30 | $0.31B  | -13.84%   |
| 2025-03-31 | $0.33B  | -20.86%   |
| 2024-12-31 | $0.06B  | -23.10%   |
| 2024-09-30 | $0.05B  | -141.16%  |
| 2024-06-30 | $0.10B  | -562.04%  |

*   **Analysis:** Revenue is growing consistently, and profit margins are very high (above 60%). However, the company is still not profitable (negative ROE). The negative ROE is improving recently and the equity is growing, meaning that the company is becoming healthier.

**7. Overall Summary**

TEM (Unknown Company) has shown strong recent performance, significantly outperforming the S&P 500. This is likely driven by recent FDA clearances and positive analyst sentiment. The company is rapidly growing its revenue and maintains high profit margins.

**Key Considerations:**

*   **High Volatility:** The high Maximum Drawdown (75%) indicates significant price volatility.
*   **Lack of Profitability:** The company is still losing money, although it is beating EPS estimates.
*   **High Valuation:** The current price is above the average analyst target price, suggesting a potentially stretched valuation.
*   **Positive Momentum:**  FDA approvals and analyst upgrades are driving momentum.
*   **Significant market change:** -2.69 change

**In conclusion:** TEM is a high-growth, high-risk stock with strong momentum. The recent pullback could present a buying opportunity, but investors should be aware of the potential for significant price swings and the company's current lack of profitability.
